Advertisement
IPHA vs MDGL
Which Stock Would AI Choose? Innate Pharma (IPHA) vs. Madrigal Pharmaceuticals (MDGL) Stock Comparison
Key Takeaways
- MDGL is a commercial-stage biopharmaceutical company with blockbuster-level revenue, while IPHA remains a pre-revenue, clinical-stage developer dependent on partnership funding.
- Recent market activity reflects diverging momentum: MDGL has been supported by accelerating Rezdiffra sales, whereas IPHA has traded in a lower range amid financing and pipeline-timeline updates.
- Risk profiles differ sharply; Madrigal carries commercial and competitive execution risk, while Innate Pharma carries binary clinical and balance-sheet risk.
- Tickeron AI Verdict: Based on observable trend consistency, revenue traction, and relative market positioning, the AI currently favors MDGL over IPHA.
- For deeper coverage, explore IPHA Major News and IPHA Today's Price Move, plus MDGL Major News and MDGL Today's Price Move.
- To see which automated strategies are favored in current conditions, browse the Trending AI Robots.
Introduction
This stock comparison examines two biopharmaceutical names at very different stages of development: Innate Pharma S.A. (IPHA), a French clinical-stage immuno-oncology company, and Madrigal Pharmaceuticals, Inc. (MDGL), a U.S.-based commercial-stage company marketing the first approved therapy for a major liver disease. Traders and investors weighing relative performance and market positioning may find the contrast instructive: one represents high-risk, catalyst-driven science still awaiting proof of commercial value, while the other offers growing, real-world revenue with execution and competition risk. Understanding how their respective risk-reward profiles behave in the current market environment is central to evaluating which name offers more compelling positioning.
IPHA Overview and Recent Performance
Innate Pharma (IPHA) is a clinical-stage biotechnology company based in Marseille, France, focused on immuno-oncology therapies, including monoclonal antibodies and antibody-drug conjugates (ADCs — engineered antibodies that deliver a toxic drug directly to cancer cells). Its lead programs include lacutamab, partnered with Sobi for T-cell lymphomas, monalizumab, co-developed with AstraZeneca in lung cancer, and the Nectin-4 ADC IPH4502 in solid tumors. Because it has no marketed products, revenue is modest and derived mainly from collaboration and licensing agreements.
In recent weeks, sentiment has been shaped by a mix of clinical updates and financing news. The company reported a strengthened cash position of roughly €96.8 million as of September 30, 2026, following a $75 million upfront payment from its Sobi partnership and a €30 million equity placement, extending its runway into early 2028. However, the timing of the PACIFIC-9 Phase 3 readout, led by AstraZeneca, was revised to the first half of 2027. The stock has traded in a comparatively low range, with weakness in its balance sheet and pre-revenue profile weighing on relative performance despite a pipeline of near-term catalysts.
MDGL Overview and Recent Performance
Madrigal Pharmaceuticals (MDGL) is a commercial-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH — a serious fatty liver disease that can progress to cirrhosis). Its product, Rezdiffra (resmetirom), is a once-daily oral therapy and the first medication approved in both the U.S. and Europe for MASH with moderate to advanced liver fibrosis. Recent market activity has reflected strong commercial momentum, with Rezdiffra net sales growing rapidly and trailing twelve-month revenue exceeding $1.1 billion, marking blockbuster status.
Investor attention in recent weeks has centered on the product's growth trajectory, expanding prescriber base, and pipeline development, including new siRNA (small interfering RNA) and related assets. The company reported third-quarter 2026 Rezdiffra product sales of approximately $431.3 million, which exceeded consensus estimates and prompted at least one analyst to raise its price target. While the company remains unprofitable due to heavy commercial investment and rising research and development expenses, its strong cash balance and growing revenue base distinguish it from earlier-stage peers.
Trending AI Robots
Tickeron operates a marketplace of hundreds of AI trading bots that monitor thousands of different tickers, each applying distinct trading styles, strategies, timeframes, and performance statistics. Because market conditions shift constantly, not every strategy suits every environment; that is why Tickeron curates a dedicated Trending AI Robots section highlighting the automated systems currently best aligned with prevailing market dynamics. These bots span multiple approaches and asset sets, allowing traders to review comparative metrics such as historical performance ranges, trade frequency, and risk profiles before selecting a strategy. Exploring this curated list offers a practical way to observe which automated approaches are gaining traction right now.
Head-to-Head Comparison
The most fundamental contrast between these two stocks is commercial maturity. Madrigal has a marketed, revenue-generating product with an expanding patient base and a defined path toward potential profitability, whereas Innate Pharma remains reliant on milestone payments, equity raises, and government research financing. This translates into a marked difference in financial strength: Madrigal holds hundreds of millions in cash and growing sales, while Innate Pharma manages a smaller cash buffer with a finite runway.
Growth drivers also differ. Madrigal's value hinges on Rezdiffra adoption, label expansion into cirrhosis, and outcomes-trial data expected in 2027 and beyond. Innate Pharma's upside is tied to binary clinical readouts across lacutamab, IPH4502, and monalizumab, where positive data could materially re-rate the stock but setbacks carry significant downside. Sector exposure is similar on the surface — both are healthcare and biotechnology — but their risk profiles are nearly opposite: commercial execution and competition for Madrigal versus clinical and financing risk for Innate Pharma. Recent momentum and market sentiment have favored the commercial-stage name.
Tickeron AI Verdict
Weighing trend consistency, revenue traction, balance-sheet resilience, and relative market positioning, Tickeron's AI would currently favor MDGL over IPHA. Madrigal offers an observable, compounding commercial catalyst in the form of growing Rezdiffra sales and a defined pipeline, which tends to produce more stable trend characteristics than a pre-revenue asset awaiting clinical readouts. Innate Pharma retains meaningful optionality through its late-stage programs, but its positioning is more dependent on uncertain catalysts and ongoing financing. This assessment is probabilistic rather than definitive and reflects the AI's current read of relative strength, not a prediction of future results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPHA is a Hold and MDGL is a Hold.
IPHA in upward trend: price may jump up because it broke its lower Bollinger Band on November 03, 2026
IPHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 44 of 54 cases where IPHA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IPHA's RSI Oscillator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 78 cases where IPHA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on October 20, 2026. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +3.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in 148 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IPHA as a result. In 98 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 50-day moving average for IPHA moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IPHA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.971) is normal, around the industry mean (3.498). P/E Ratio (-2.824) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (55.556) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MDGL sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for MDGL moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MDGL entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 65 cases where MDGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.630) is normal, around the industry mean (3.498). P/E Ratio (-28.565) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. MDGL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IPHA | MDGL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 17 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 27 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 61 | 75 | |
P/E GROWTH RATING 1..100 | 26 | 18 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDGL's Valuation (15) in the Pharmaceuticals Other industry is in the same range as IPHA (17) in the null industry. This means that MDGL’s stock grew similarly to IPHA’s over the last 12 months.
MDGL's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is significantly better than the same rating for IPHA (100) in the null industry. This means that MDGL’s stock grew significantly faster than IPHA’s over the last 12 months.
MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as IPHA (98) in the null industry. This means that MDGL’s stock grew similarly to IPHA’s over the last 12 months.
IPHA's Price Growth Rating (61) in the null industry is in the same range as MDGL (75) in the Pharmaceuticals Other industry. This means that IPHA’s stock grew similarly to MDGL’s over the last 12 months.
MDGL's P/E Growth Rating (18) in the Pharmaceuticals Other industry is in the same range as IPHA (26) in the null industry. This means that MDGL’s stock grew similarly to IPHA’s over the last 12 months.
| IPHA | MDGL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 87% | N/A |
| MACD ODDS (%) | 2 days ago 78% | N/A |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| Advances ODDS (%) | 2 days ago 74% | 12 days ago 75% |
| Declines ODDS (%) | 5 days ago 85% | 2 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 70% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IPHA’s FA Score shows that 2 FA rating(s) are green while MDGL’s FA Score has 3 green FA rating(s).
- IPHA’s FA Score: 2 green, 3 red.
- MDGL’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IPHA’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).
- IPHA’s TA Score: 5 bullish, 4 bearish.
- MDGL’s TA Score: 4 bullish, 3 bearish.
Price Growth
IPHA (@Biotechnology) experienced а -1.37% price change this week, while MDGL (@Biotechnology) price change was -7.14% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
Reported Earning Dates
IPHA is expected to report earnings on Mar 25, 2027.
MDGL is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (-2.35% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IPHA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IPHA has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHA jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To IPHA | 1D Price Change % | ||
|---|---|---|---|---|
| IPHA | 100% | +2.86% | ||
| MDGL - IPHA | 43% Loosely correlated | -0.12% | ||
| APLM - IPHA | 36% Loosely correlated | +10.10% | ||
| ATYR - IPHA | 36% Loosely correlated | +5.31% | ||
| CCXI - IPHA | 34% Loosely correlated | N/A | ||
| FENC - IPHA | 33% Loosely correlated | +4.47% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AVEM | 83.28 | 1.41 | +1.72% |
| Avantis Emerging Markets Equity ETF (AVEM) | |||
| PCN | 11.07 | 0.16 | +1.47% |
| PIMCO Corporate & Income Strategy Fund | |||
| PGHY | 19.07 | 0.23 | +1.24% |
| Invesco Global ex-US High Yield Corporate Bond ETF (PGHY) | |||
| FLXI | 48.00 | N/A | N/A |
| Invesco Flexible Income ETF (FLXI) | |||
| PBOC | 31.02 | N/A | N/A |
| PGIM S&P 500 Buffer 20 ETF - October (PBOC) | |||